Phaseline

Companies › Endo USA Inc., a Keenova Therapeutics Company

Endo USA Inc., a Keenova Therapeutics Company: clinical trials, targets and expected readouts

1 active drug program in 6 registered trials: 5 Phase 4, 1 Phase 3; Genitourinary, Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Collagenase Clostridium Histolyticum (KN3835)
Collagen hydrolytic enzyme
COL1A2, COL1A1, COL2A1, COL3A1, COL4A1Phase 3Flexible Hammertoe; Peyronie Disease; Peyronie's Disease; Dupuytren Disease of Finger …Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05777031Collagenase Clostridium Histolyticum (KN3835)Phase 4Peyronie DiseaseGenitourinaryJan 2027
NCT04786106Collagenase Clostridium Histolyticum (KN3835)Phase 4Peyronie's DiseaseGenitourinaryFeb 2027
NCT03406338Collagenase Clostridium Histolyticum (KN3835)Phase 4Dupuytren Disease of FingerOtherSep 2027
NCT07759362Collagenase Clostridium Histolyticum (KN3835)Phase 3Flexible HammertoeOtherDec 2027
NCT06649539Collagenase Clostridium Histolyticum (KN3835)Phase 4Peyronie DiseaseGenitourinaryOct 2029
NCT03192020Collagenase Clostridium Histolyticum (KN3835)Phase 4Dupuytren ContractureOtherMay 2031

Targets

COL1A2 (1) COL1A1 (1) COL2A1 (1) COL3A1 (1) COL4A1 (1)

Companies with the same targets

–

Companies built like this

Hansa Biopharma Heron Therapeutics CellTherX Innovacell CUTISS

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.